Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Express Scripts
Dow
Mallinckrodt
AstraZeneca

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR BIAXIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Biaxin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00006219 ↗ Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Completed National Cancer Institute (NCI) Phase 2 2000-08-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00006219 ↗ Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma Completed Mayo Clinic Phase 2 2000-08-01 RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.
NCT00151203 ↗ Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma Completed Celgene Corporation Phase 2 2004-12-01 PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
NCT00151203 ↗ Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma Completed Weill Medical College of Cornell University Phase 2 2004-12-01 PRIMARY STUDY OBJECTIVES - To evaluate the efficacy of the combination of clarithromycin (Biaxin®), lenalidomide (Revlimid™), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed multiple myeloma (MM). - To evaluate the safety of the combination of clarithromycin, lenalidomide, and dexamethasone as an induction therapy for patients with newly diagnosed MM. SECONDARY STUDY OBJECTIVES - To examine the role of clarithromycin on the pharmacokinetic properties of dexamethasone and lenalidomide. - To examine the angiogenesis profile in untreated patients and in patients receiving induction therapy.
NCT00182663 ↗ Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant Completed National Cancer Institute (NCI) Phase 2 2003-06-01 This phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant. Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone also works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving thalidomide together with dexamethasone and clarithromycin after a transplant may be an effective treatment for multiple myeloma
NCT00182663 ↗ Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant Completed Fred Hutchinson Cancer Research Center Phase 2 2003-06-01 This phase II trial studies the side effects and how well giving thalidomide, dexamethasone, and clarithromycin together works in treating patients with multiple myeloma previously treated with transplant. Biological therapies, such as thalidomide and clarithromycin, may stimulate the immune system in different ways and stop cancer cells from growing. Dexamethasone also works in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving thalidomide together with dexamethasone and clarithromycin after a transplant may be an effective treatment for multiple myeloma
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Biaxin

Condition Name

Condition Name for Biaxin
Intervention Trials
Healthy 13
Multiple Myeloma 10
Idiopathic Hypersomnia 2
Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Biaxin
Intervention Trials
Neoplasms, Plasma Cell 15
Multiple Myeloma 15
Pneumonia 3
Bronchitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Biaxin

Trials by Country

Trials by Country for Biaxin
Location Trials
United States 97
China 24
Canada 19
Korea, Republic of 4
India 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Biaxin
Location Trials
New York 9
Arizona 7
Washington 6
Missouri 6
California 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Biaxin

Clinical Trial Phase

Clinical Trial Phase for Biaxin
Clinical Trial Phase Trials
Phase 4 2
Phase 3 10
Phase 2/Phase 3 2
[disabled in preview] 25
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Biaxin
Clinical Trial Phase Trials
Completed 37
Active, not recruiting 4
Recruiting 4
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Biaxin

Sponsor Name

Sponsor Name for Biaxin
Sponsor Trials
Abbott 6
Weill Medical College of Cornell University 5
Ranbaxy Laboratories Limited 5
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Biaxin
Sponsor Trials
Industry 43
Other 40
NIH 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Medtronic
Harvard Business School
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.